Physician

Thomas Christian Weart, M.D.

According to 2025 Medicare claims, Thomas Weart, M.D. (NPI: 1518226034) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Chesterfield, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23235-4730.

Weart's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 643 traditional Medicare patients, billed 133,399 HCPCS/CPT codes, and received $2,731,678 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,045 prescription claims across 180 beneficiaries totaling $2,072,491 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 51 claims. Open Payments data shows 71 records totaling $34,395. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $242,219 to $2,731,678. Similarly, Part D prescription costs have risen steadily, from $1,415 to $2,072,491. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	269	14,775	$242,219
2019	774	108,169	$1,485,889
2020	772	126,630	$2,260,178
2021	677	112,642	$2,078,422
2022	646	120,208	$2,128,579
2023	695	166,942	$2,708,146
2024	643	133,399	$2,731,678

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	14	36	$1,415
2016	N/R	28	$48,044
2017	22	55	$20,361
2018	54	174	$126,270
2019	107	655	$521,815
2020	114	776	$1,136,571
2021	130	736	$1,473,031
2022	147	986	$2,113,030
2023	165	935	$1,886,393
2024	180	1,045	$2,072,491

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	51	$4,312
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	112	360	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	323	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	288	608	$64
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	87	154	$46
96372	Injection of drug or substance under skin or into muscle	90	227	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	29	805	$517,115
Calquence	Acalabrutinib Maleate	34	1,020	$492,418
Imbruvica	Ibrutinib	13	364	$212,242
Tagrisso	Osimertinib Mesylate	13	390	$196,045
Xtandi	Enzalutamide	11	330	$147,556

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	69	$1,480	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$32,915	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas Christian Weart, M.D.?

Tedicare shows public-source Medicare data for Thomas Christian Weart, M.D. (NPI 1518226034), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas Christian Weart, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Thomas Christian Weart, M.D.?

Thomas Christian Weart, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Thomas Christian Weart, M.D. have Open Payments data?

Thomas Christian Weart, M.D. has 71 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.